Cryoablation for renal tumors: current status.
OBJECTIVE
To review the evolution and current status of cryoablation for renal tumors.


RESULTS
Cryoablation is the most evaluated probe ablative method for the treatment of small renal masses. It is associated with high efficacy and low morbidity. New data on intermediate and long-term oncological outcomes are now available. Five and 10-year cancer-specific survival are 93 and 81%, respectively. Renal cryoablation is most commonly performed percutaneously or laparoscopically. Recently, single-port laparoscopic and natural orifice transluminal endoscopic surgery approaches have also been employed for renal cryotherapy.


CONCLUSIONS
With careful patient selection, the intermediate-term and long-term oncologic outcomes after cryoablation for kidney tumors are satisfactory. Combination with new technologies and further development of imaging techniques can potentially expand the range of indications of the procedure.
Berger
Andre
A
Center for Laparoscopic and Robotic Surgery, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Kamoi
Kazumi
K
Gill
Inderbir S
IS
Aron
Monish
M
D000818:Animals; D002292:Carcinoma, Renal Cell / Q000601:surgery*; D003452:Cryosurgery / Q000639:trends*; D006801:Humans; D007680:Kidney Neoplasms / Q000601:surgery*; D010535:Laparoscopy / Q000639:trends; D009392:Nephrectomy / Q000639:trends